Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial

• Main Authors: Xiaoyuan Huang (Author), Ting Fan (Author), Li Li (Author), Xuanxuan Nian (Author), Jiayou Zhang (Author), Xuefen Gao (Author), Wei Zhao (Author), Wei Chen (Author), Zhaoqing Zhang (Author), Zhihao Yao (Author), Xixin Han (Author), Jinrong Shi (Author), Ying Wang (Author), Haihe Bian (Author), Nianmin Shi (Author), Xinguo Li (Author), Kai Duan (Author), Guohua Li (Author), Xiaoming Yang (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background A quadrivalent split influenza vaccine IIV4-W against both influenza A and B viruses is urgently needed. Methods To evaluate the safety and immunogenicity of IIV4-W in people aged 3-60 years, 2400 participants recruited in a double-blind phase III trial and were randomly assigned to the I...